InsiderTrades.com logo
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

SCLP Insider Trading

Insider Ownership Percentage: 5.72%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): GBX 0

Scancell Insider Trading History Chart

This chart shows the insider buying and selling history at Scancell by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scancell Share Price & Price History

Current Price: GBX 9.55
Price Change: +0.30 (1.20%)
As of 04/18/2024 01:00 AM ET

This chart shows the closing price history over time for SCLP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

Scancell Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2022Martin DiggleInsiderBuy250,000GBX 12£30,000
11/2/2021Martin DiggleInsiderBuy200,000GBX 19£38,000
9/9/2021Lindy DurrantInsiderSell2,380,952GBX 21£499,999.92
7/29/2021Martin DiggleInsiderBuy200,000GBX 19£38,000
6/4/2021Martin DiggleInsiderBuy350,000GBX 19£66,500
4/29/2021Martin DiggleInsiderBuy400,000GBX 20£80,000
See Full Table
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

SEC Filings (Institutional Ownership Changes) for Scancell (LON:SCLP)

45.65% of Scancell stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Scancell logo
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Read More on Scancell

Today's Range

Now: GBX 9.55
Low: 9.33
High: 9.58

50 Day Range

MA: GBX 10.51
Low: 9.55
High: 11.95

52 Week Range

Now: GBX 9.55
Low: 7.59
High: 18.30

Volume

246,018 shs

Average Volume

436,055 shs

Market Capitalization

£88.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story